IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer’s - POTOMAC, MD / ACCESS Newswire / March ...
In March 2025, Merck Sharp & Dohme LLC announced a study are to learn if people who receive V940 and pembrolizumab are alive ...
BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...
vTv Therapeutics, a biopharmaceutical company based in High Point, has received clearance from the U.S. Food and Drug ...
Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced the successful completion of the Phase III clinical study ...
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
SUMMIT, N.J. , March 18, 2025 /PRNewswire/ -- A 60-patient, randomized, double-blind, placebo-controlled phase I clinical study of VAS101 (topical curcumin gel) in osteoarthritis (OA) is underway.
Vietnam Investment Review on MSN2d
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 for Platinum resistant Ovarian CancerSAN FRANCISCO and SUZHOU, China, March 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
In March 2025, Celgene announced a study is to compare the effectiveness and safety of golcadomide in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback